Substituted pyrazolo[3,4-b]pyridines as ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) modulators

A compound of Formula (XI):

• or a pharmaceutically acceptable salt thereof,
• wherein:
• R30 is C1-C6 alkyl, C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, phenyl, or monocyclic heteroaryl, wherein the C1-C6 alkyl, phenyl, or monocyclic heteroaryl is optionally substituted with one, two, or three independently selected R37 substituents;
• each R37 is independently halogen, CN, C1-C4 alkyl, C1-C4 fluoroalkyl, NR1AR1A, OR1B, or SR1B;
• R31 is H, halogen, C1-C6 alkyl, C1-C4 fluoroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, or phenyl, wherein the phenyl is optionally substituted with one, two, or three independently selected R38 substituents;
• each R38 is independently halogen, CN, C1-C4 alkyl, C1-C4 fluoroalkyl, NR1AR1A, OR1B, or SR1B;
• R32 is H, halogen, CN, C1-C6 alkyl, C1-C4 fluoroalkyl, C1-C6 alkyl-OH, C2-C4 alkenyl, C2-C4 alkynyl, NR1AR1A, OR1B, OC1-C4 fluoroalkyl, SR1B, monocyclic C2-C6 heterocycloalkyl, phenyl, or monocyclic 5- or 6-membered heteroaryl, wherein the C1-C6 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, phenyl, or monocyclic 5- or 6-membered heteroaryl is optionally substituted with one, two, or three independently selected R39 substituents;
• each R39 is independently halogen, CN, C1-C4 alkyl, C1-C4 fluoroalkyl, NR1AR1A, OR1B, or SR1B;
• Ya is CH;
• R34 is S(O)2NR1AR1A;
• w is 0, 1, 2, or 3;
• each R35 is independently halogen, CN, C1-C6 alkyl, C1-C6 haloalkyl, C2-C4 alkynyl, OR1B, or cycloalkyl;
• each R1A is independently H, C1-C6 alkyl, CH2-phenyl, cycloalkyl, or aryl;
• and
• each R1B is independently H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl.